Effect of ganglioside combined with edaravone on short-term prognosis of patients with acute cerebral infarction

Abstract

Objective To investigate the effect of ganglioside combined with edaravone on short-term prognosis of patients with acute cerebral infarction, and provide reference for improving the prognosis of patients. Methods 60 patients with acute cerebral infarction in our hospital from January 2014 to December 2015 were selected as study subjects, were divided into the treatment group and the control group according to the random number table method, 30 cases in each group. The control group was treated with edaravone, and the treatment group was treated with ganglioside on the basis of the control group. After 2 weeks of treatment, the clinical efficacy and serum levels of neuron specific enolase (NSE), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) were compared between the two groups. The patients were followed up for 3 months, Barthel index (BI), neurological deficit score (NIHSS) were compared between the two groups. Results After 2 weeks of treatment, the total effective rate of the treatment group was 93.33%, significantly higher than 73.33% of the control group (P 0.05). Conclusion Ganglioside combined with edaravone can improve the clinical efficacy in patients with acute cerebral infarction, improve short-term life ability and neural function, without increase in the incidence of adverse reactions, worthy of attention. Key words: Ganglioside; Edaravone; Acute cerebral infarction; Short-term prognosis; Analysis